A Randomized Active-Controlled, Double-Blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer

SMT112-3005 HARMONi-GI3 The main goal of this study is to test the safety and benefits of the study drug Ivonescimab when it is given with drug called FOLFOX, a mix a platinum-based chemo drug used to treat certain cancers, most notably colorectal cancer. This treatment will be compared to another drug, Avastin, which is also given with FOLFOX, for people receiving their first treatment for cancer. This drug AK-112 is a new drug and has not been approved for use or sale by the U.S. Food and Drug Administration or local health authorities. Avastin is an approved drug.

Departments